Streetbeat News

Products Services

ELTX

Elicio Therapeutics announced interim data from the ongoing Phase 1 study of ELI-002 in patients with mutant KRAS-driven tumors at high risk for relapse at the 2023 ASCO Meeting, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 3:58 pm

MSFT

Microsoft 365, a product suite owned by Microsoft Corp (NASDAQ: MSFT), experienced an outage affecting over 15,000 users on Monday. Around 85% of the issues were related to Outlook, with 10% related to the website and 5% to server connection.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 3:58 pm

NTES

Bernstein analyst Robin Zhu initiates coverage on NetEase Inc (NASDAQ:NTES) with an Outperform rating and a price target of $120. NetEase has shown consistent growth and is expanding overseas with new game launches. The company is also expected to benefit from generative AI development in the gaming industry.

Portfolio Pulse from Anusuya Lahiri

June 05, 2023 | 3:50 pm

AAPL

META

Apple Inc (AAPL) is expected to showcase its AR/VR headset at the Worldwide Developers Conference (WWDC). Since the rumors started in June 2020, Apple's stock has gained 109.76%. The headset is expected to be released in 2023, with a budget-friendly version to follow. It will feature 4K micro OLED displays, over a dozen cameras, and a new operating system called xrOS.

Portfolio Pulse from AJ Fabino

June 05, 2023 | 3:47 pm

PRTG

Portage Biotech reported updated interim data from the Phase 1 trial for the treatment of advanced melanoma and metastatic non-small cell lung cancer at the 2023 ASCO Annual Meeting, leading to higher trading of its shares.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 3:39 pm

SYTA

Siyata Mobile announced receiving $400,000 in new orders for its SD7 Handsets and VK7 Vehicles Kits, leading to a higher trading of its shares.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 3:35 pm

GILD

Gilead's Kite's Yescarta CAR T-cell therapy shows statistically significant overall survival (OS) for initial treatment of R/R LBCL, with a 27.4% reduction in risk of death and a 38% relative improvement in OS. The data was highlighted at ASCO 2023 and published in the New England Journal of Medicine.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 3:27 pm

MGRX

Mangoceuticals shares are moving higher as the company teases a big week ahead with press and updates on their Twitter account. The company promises to continue sharing media and commercials for their @mango_rx product.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 3:26 pm

BLPH

Bellerophon Therapeutics announced top-line results from its Phase 3 REBUILD trial for INOpulse, which failed to meet its primary endpoint. The trial showed minimal difference between INOpulse and the placebo, with none of the secondary endpoints reaching statistical significance. Shares of BLPH are down 85%.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 2:57 pm

TSXV:GBLT

GBLT Corp. has completed the necessary testing and legal assurances to distribute its Dr. Senst CBD products in Germany. The company plans to leverage its established distribution network with major retailers and distributors to expand its product offerings and market share.

Portfolio Pulse from Vuk Zdinjak

June 05, 2023 | 2:56 pm